Sanofi-Aventis And Xuanwu Hospital Capital Medical University To Set Up Regeneration Lab
This article was originally published in PharmAsia News
Executive Summary
Sanofi-Aventis will cooperate with Xuanwu Hospital Capital Medical University to set up a regeneration laboratory to focus on research of the central nervous system, metabolic disorders and geriatric diseases. Since 2007, the company has established strategic partnerships with China's leading academic institutions. These include Tianjin Institute of Hematology and Blood Diseases Hospital, which comes under the Chinese Academy of Medical Sciences; and Shanghai Institute for Biological Sciences. Sanofi-Aventis disclosed that it is likely to launch a new oncology drug by the end of the year. The company's China operation currently prioritizes R&D and it will continue to build close partnerships with academic institutions. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.